Feb 08, 2018
Outcome from DSMB Safety Review and Extension of TACTI-mel Phase I Clinical Trial
Jan 31, 2018
Immutep Limited Announces Milestone Payment from Chinese Partner EOC Pharma
Dec 11, 2017
Operational Update
Nov 28, 2017
Prima BioMed Becomes Immutep
Nov 20, 2017
FAQ – Change of company name from ‘Prima BioMed Limited’ to ‘Immutep Limited’
Prima Secures European Patent Grant for Lead Product IMP321 in Cancer
Nov 19, 2017
Prima BioMed Changes its Name to Immutep Ltd
Nov 14, 2017
Eftilagimod Alpha (LAG-3Ig or IMP321) Pre-IND Meeting with the FDA
Nov 07, 2017
New Eftilagimod Alpha (LAG-3Ig or IMP321) Data for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting
Oct 30, 2017
Dr. Frédéric Triebel Presented at the World Immunotherapy Congress 2017
Oct 18, 2017
Dr. Frédéric Triebel presenting at the World Immunotherapy Congress 2017
Oct 16, 2017
IMP321 New Data Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting
Sep 07, 2017
Prima Secures Japanese Patent Grant for IMP731 Antibody
Sep 05, 2017
Prima Secures Japanese Patent Grant for Lead Product IMP321 in Infectious Disease
Aug 29, 2017
Prima BioMed and Monash University Receive Funding Grant for LAG-3 Research Project
